tradmap

VOR Earnings Vor Biopharma Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$71 -$35 $0 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$696M -$348M $0 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-121% 151% 424% 0% 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$378 -$189 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$2B $75M $2B $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-1049% -451% 146% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–21 of 21
Q2 20262026-06-30-5.802026-08-1110-Q
Q1 20262026-03-31-5.112026-05-1310-Q
FY 20252025-12-31-70.502026-03-3010-K
Q3 20252025-09-30-378.112025-11-1310-Q
Q2 20262025-06-30-256.882026-08-1110-Q
Q1 20262025-03-31-5.212026-05-1310-Q
FY 20252024-12-31-34.032026-03-3010-K
Q3 20252024-09-30-25.252025-11-1310-Q
Q2 20252024-06-30-0.862025-08-1210-Q
Q1 20252024-03-31-0.452025-05-1410-Q
FY 20242023-12-31-1.752025-03-2010-K
Q3 20242023-09-30-1.372024-11-0710-Q
Q2 20242023-06-30-0.882024-08-0810-Q
Q1 20242023-03-31-0.432024-05-0910-Q
FY 20232022-12-31-2.332024-03-2010-K
Q3 20232022-09-30-1.812023-11-0710-Q
Q2 20232022-06-30-1.192023-08-1010-Q
Q1 20232022-03-31-0.612023-05-1110-Q
FY 20222021-12-31-2.102023-03-2310-K
Q3 20222021-09-30-1.622022-11-1010-Q
Q2 20222021-06-30-1.132022-08-1110-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.